Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Charles River Laboratories › T. Rowe Price Associates, Inc. now owns 6.3% of CRL as a passive inves Fund moves
Stake · was 6.3%
Shares owned
Why it stands out A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0000080255-26-000686
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Nov 6 · filed 3 days later
Routine share withholding; mechanical by default.
Insider filing
Traded Oct 22 · filed 4 days later
Derivative exercise or conversion — not an open-market buy.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Feb 28, 2026 Federal contract · $5.3M obligated Department of Health and Human Services awarded Charles River Laboratories: $5.31M obligated to date Aug 5, 2026 Company filing · Form 8-K · Results Reported its results Aug 5, 2026 Insider · Their largest sale since 2022 Officer sold ~$1.33M of CRL shares in the open market Aug 6, 2026 5% stake FMR LLC reported a passive stake (13G) of 8.8% Aug 6, 2026 Insider · 2 people Insiders: 10 sales (~$2.8M) Aug 10, 2026 Insider Director sold ~$7.9M of CRL shares in the open market Aug 11, 2026 Insider · 2 people Insiders: 2 sales (~$2.9M) Aug 13, 2026 5% stake Invesco Ltd. reported a passive stake (13G) of 6.2% Aug 18, 2026 Federal contract · $372K obligated Department of Health and Human Services awarded Charles River Laboratories: $372K obligated to date Aug 18, 2026 Insider Director sold ~$163K of CRL shares in the open market Aug 19, 2026 Insider Officer sold ~$600K of CRL shares in the open market Aug 25, 2026 Insider Director sold ~$10.1M of CRL shares in the open market Aug 31, 2026 Federal contract · $1.0M obligated Department of Health and Human Services awarded Charles River Laboratories: $1.01M obligated to date Sep 8, 2026 5% stake FMR LLC reported a passive stake (13G) of 10.2% Sep 17, 2026 Federal contract · $2.7M obligated Department of Health and Human Services awarded Charles River Laboratories: $2.68M obligated to date Sep 17, 2026 Federal contract · $8.2M obligated Department of Health and Human Services awarded Charles River Laboratories: $8.25M obligated to date Sep 25, 2026 Federal contract · $340K obligated Department of Health and Human Services awarded Charles River Laboratories: $340K obligated to date What came next Oct 5, 2026 Insider Officer sold ~$303K of CRL shares in the open market Oct 21, 2026 Insider Officer sold ~$743K of CRL shares in the open market Oct 22, 2026 Insider Director sold ~$8.41M of CRL shares in the open market Nov 4, 2026 Company filing · Form 8-K · Results Reported its results
Nov 5, 2026